Insulin pens are a necessity, not a luxury: Addressing inequitable access to diabetes treatment in South Africa’s public sector
DOI:
https://doi.org/10.7196/SAMJ.2025.v116i3.3606Keywords:
Diabetes care, Insulin pen accessibility, Glycemic controlAbstract
Diabetes is a growing public health crisis in South Africa (SA), driven by urbanisation, sedentary lifestyles, poor dietary habits and an ageing population. The country has one of the highest diabetes prevalence rates in sub-Saharan Africa, with millions affected, many of whom remain undiagnosed. The disease disproportionately impacts low-income communities, where limited healthcare access and late diagnoses lead to severe complications and economic strain. While insulin pens improve glycaemic control and patient adherence, they remain largely inaccessible in the public sector owing to high costs and restrictive procurement policies. Government reliance on vials and syringes exacerbates treatment disparities, increasing the risk of medication errors and poor health outcomes. Addressing these barriers requires policy reform, expanded subsidies and improved procurement strategies to ensure equitable access to insulin pens. By prioritising patient-centred diabetes care, SA can reduce hospitalisations, enhance treatment adherence and alleviate the broader economic and healthcare burden of diabetes.
References
1. Mendenhall E, Kohrt BA, Norris SA, Ndetei D, Prabhakaran D. Non-communicable disease syndemics: Poverty, depression, and diabetes among low-income populations. Lancet 2017;389(10072):951-963. https://doi.org/10.1016/s0140-6736(17)30402-6
2. Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022;183:109119. https://doi.org/10.1016/j.diabres.2021.109119
3. Hill-Briggs F, Adler NE, Berkowitz SA, et al. Social determinants of health and diabetes: A scientific review. Diabetes Care 2020;44(1):258. https://doi.org/10.2337/dci20-0053
4. Simeone JC, Shah S, Ganz ML, et al. Healthcare resource utilisation and cost among patients with type 1 diabetes in the United States. J Man Care Specialty Pharm 2020;26(11):1399-1410. https://doi. org/10.18553/jmcp.2020.26.11.1399
5. Beran D, Hirsch IB, Yudkin JS. Why are we failing to address the issue of access to insulin? A national and global perspective. Diabetes Care 2018;41(6):1125-1131. https://doi.org/10.2337/dc17-2123
6. Piotie PN, Webb EM, Rheeder P. Suboptimal control and failure to intensify therapy for South Africans with type 2 diabetes: An audit of diabetes management at primary health care facilities. J Endocrinol Metab Diabetes S Afr 2024;29(1):37-42. https://doi.org/10.1080/16089677.2024.2311497
7. Masuku SD, Lekodeba N, Meyer-Rath G. The costs of interventions for type 2 diabetes mellitus, hypertension and cardiovascular disease in South Africa – a systematic literature review. BMC Public Health 2022;22(1):2321. https://doi.org/10.1186/s12889-022-14730-4
8. Valladales-Restrepo LF, Delgado-Araujo AC, Oyuela-Gutiérrez MC, Ospina-Arzuaga HD, Machado- Alba JE. Level of satisfaction among patients using insulin administered by pen vs vial/syringe. An observational prospective study. Patient Pref Adherence 2025;19:65-74. https://doi.org/10.2147/PPA. S491944
9. Statistics South Africa. Non-communicable diseases in South Africa: Findings from death notifications, 2008 - 2018. Report No. 03-08-01. Pretoria: Stats SA, 2023. https://www.statssa.gov.za/publications/ Report-03-08-01/Report-03-08-012018.pdf (accessed 16 March 2026).
10. Pheiffer C, Pillay-van Wyk V, Turawa E, Levitt N, Kengne AP, Bradshaw D. Prevalence of type 2 diabetes in South Africa: A systematic review and meta-analysis. Int J Environ Res Public Health 2021;18(11):5868. https://doi.org/10.3390/ijerph18115868
11. International Diabetes Federation. Diabetes impacts the mental well-being of 3 in 4 people with the condition. Brussels: IDF, 2024. https://idf.org/news/diabetes-hidden-burden/ (accessed 18 April 2025).
12. Seggelke SA, Hawkins RM, Gibbs J, Rasouli N, Wang CCL, Draznin B. Effect of glargine insulin delivery method (pen device versus vial/syringe) on glycemic control and patient preferences in patients with type 1 and type 2 diabetes. Endocr Pract 2014;20(6):536-539. https://doi.org/10.4158/
EP13404.OR
13. National Department of Health, South Africa. Notice: Guidance on insulin switching. insulin pen sets to insulin vials and human insulin products to insulin analog products. Pretoria: NDoH, 2025. https://www.health.gov.za/wp-content/uploads/2025/10/Circular-Update-on-Insulin-Availability-17- October-2025.pdf (accessed 18 April 2025).
14. Doctors Without Borders. Novo Nordisk’s insulin pen shortage impacts thousands in South Africa. MSF, 16 May 2024. https://www.msf.org.za/news-and-resources/press-release/novo-nordisks-insulin- pen-shortage-impacts-thousands-south-africa (accessed 18 April 2025).
15. Masierek M, Nabrdalik K, Janota O, Kwiendacz H, Macherski M, Gumprecht J. The review of insulin pens – past, present, and look to the future. Front Endocrinol 2022;13:827484. https://doi.org/10.3389/ fendo.2022.827484
16. Slabaugh SL, Bouchard JR, Li Y, Baltz JC, Meah YA, Moretz DC. Characteristics relating to adherence and persistence to basal insulin regimens among elderly insulin-naïve patients with type 2 diabetes: Pre-filled pens versus vials/syringes. Adv Ther 2015;32(12):1206-1221. https://doi.org/10.1007/ s12325-015-0266-5
17. Zuberi Z, Sauli E, Cun L, et al. Insulin-delivery methods for children and adolescents with type 1 diabetes. Ther Adv Endocrinol Metab 2020;11:2042018820906016. https://doi.org/10.1177/2042018820906016
18. Pearson TL. A practical review of insulin pen devices. EMJ Diabet 2014;2:58-64. https://doi.
org/10.33590/emjdiabet/10312668
19. Aanstoot H-J, Rodriguez H, Weinzimer S, Vint N, Koeneman L. Precision dosing of rapid-acting insulin matters. Diabetes Technol Therapeutics 2020;22(5):346-351. https://doi.org/10.1089/ dia.2019.0374
20. Leuschner M, Strydom M, Steenkamp V. From economics to health outcomes: Delving into the significance of reduced insulin prices. S Afr Med J 2024;114(8):43-44. https://doi.org/10.7196/ SAMJ.2024.v114i8.2014
21. Kamrul-Hasan A, Hannan MA, Alam MS, et al. Comparison of simplicity, convenience, safety, and cost-effectiveness between use of insulin pen devices and disposable plastic syringes by patients with type 2 diabetes mellitus: A cross-sectional study from Bangladesh. BMC Endocrine Dis 2023;23(1):37. https://doi.org/10.1186/s12902-023-01292-8
22. Lasalvia P, Barahona-Correa JE, Romero-Alvernia DM, et al. Pen devices for insulin self-administration compared with needle and vial: Systematic review of the literature and meta-analysis. J Diabetes Sci Technol 2016;10(4):959-966. https://doi.org/10.1177/1932296816633721
23. Ward, R. SusQI case study – improving the environmental impact of patients with diabetes and on insulin 2023. https://networks.sustainablehealthcare.org.uk/resources/susqi-case-study-improving- environmental-impact-patients-diabetes-and-insulin (accessed 12 October 2023).
24. Pillay SP. Pilot study involving the use of point-of-care glycated haemoglobin (HbA1c) testing for screening and monitoring of diabetes mellitus in the public healthcare sector in KwaZulu-Natal. J Endocrinol Metab Diabetes S Afr 2020;25(3):63-69. https://doi.org/10.1080/16089677.2020.1793488
25. World Health Organization. Diabetes is a family affair in Kenya. WHO Africa, 2019. https://www.afro. who.int/news/diabetes-family-affair-kenya (accessed 18 April 2025).
26. Bayat S, Perumal-Pillay VA, Suleman F. Availability and pricing of insulin and related diagnostics in South Africa. J Pharmaceut Policy Pract 2024;17(1):2372467. https://doi.org/10.1080/20523211.2024 .2372467
27. National Strategic Plan for the prevention and control of non-communicable diseases in South Africa. S Afr J Pub Health 2022;5(3):67. https://doi.org/10.7196/SAJPH.2022.v5.i3.174
28. Barber MJ, Gotham D, Bygrave H, Cepuch C. Estimated sustainable cost-based prices for diabetes medicines. JAMA Network Open 2024;7(3):e243474-e. https://doi.org/10.1001/ jamanetworkopen.2024.3474
29. Malatji T, Wamukuo J, Hyera F. An analysis of the direct cost of renal dialysis provided through a public-private partnership at a tertiary hospital in Limpopo Province, South Africa. S Afr Med J 2019;109(8):577-581. https://doi.org/10.7196/SAMJ.2019.v109i8.13597
30. Ball D, Ewen M, Laing R, Beran D. Insulin price components: Case studies in six low/middle-income countries. BMJ Glob Health 2019;4(5):e001705.
31. National Department of Health, South Africa. Circular: Availability of insulin pen sets 2024. Pretoria: NDoH, 2024. https://www.health.gov.za/wp-content/uploads/2024/06/Circular_Insulin- Award_Final_07-May-2024.pdf (accessed 18 April 2025).
32. World Health Organization. Kenya: Essential Medicines List 2023 (English). Geneva: WHO, 2023. https://www.who.int/publications/m/item/kenya--essential-medicines-list-2023-(english) (accessed 18 April 2025).
33. ModernMedia. Sanofi commits to affordable insulin pens for diabetic patients. Quicknews, 15 August 2024. https://www.quicknews.co.za/2024/08/15/sanofi-commits-to-affordable-insulin-pens- for-diabetic-patients/ (accessed 15 August 2024).
34. Gray A, Riddin J, Jugathpal J. Health care and pharmacy practice in South Africa. Can J Hosp Pharm 2016;69(1):36. https://doi.org/10.4212/cjhp.v69i1.1521
35. Mathose TT, Mash R. Factors influencing insulin initiation in primary care facilities in Cape Town, South Africa. S Afr Family Pract 2023;65(1):5656. https://doi.org/10.4102/safp.v65i1.5656
36. Wirtz VJ, Hogerzeil HV, Gray AL, et al. Essential medicines for universal health coverage. Lancet 2017;389(10067):403-476. https://doi.org/10.1016/S0140-6736(16)31599-9
Downloads
Published
Issue
Section
License
Copyright (c) 2026 B Jordaan, M Leuschner, V Steenkamp
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
